Caris Life Sciences, Inc. (CAI)
31.76
+1.50
(+4.97%)
USD |
NASDAQ |
Oct 15, 16:00
32.41
+0.65
(+2.05%)
After-Hours: 06:03
Caris Life Sciences Research and Development Expense (Quarterly) : 32.36M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.36M |
| March 31, 2026 | 31.32M |
| December 31, 2025 | 31.84M |
| September 30, 2025 | 21.62M |
| June 30, 2025 | 25.05M |
| Date | Value |
|---|---|
| March 31, 2025 | 23.07M |
| December 31, 2024 | 27.11M |
| September 30, 2024 | 27.64M |
| June 30, 2024 | 24.79M |
| March 31, 2024 | 34.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| CareDx, Inc. | 22.38M |
| Natera, Inc. | 228.07M |
| Myriad Genetics, Inc. | 25.00M |
| BioRestorative Therapies, Inc. | 1.926M |
| Exagen, Inc. | 1.426M |